Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pia Sormani, M.
Right arrow Articles by Filippi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pia Sormani, M.
Right arrow Articles by Filippi, M.
Related Collections
Right arrow MRI
Right arrow Multiple sclerosis
Neurology 2002;58:417-421
© 2002 American Academy of Neurology

MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients

Maria Pia Sormani, PhD, Paolo Bruzzi, MD, Giancarlo Comi, MD and Massimo Filippi, MD

From the Unit of Clinical Epidemiology and Trials (Drs. Sormani and Bruzzi), National Institute for Cancer Research, Genoa, and Neuroimaging Research Unit (Drs. Sormani and Filippi) and Clinical Trials Unit (Dr. Comi), Department of Neuroscience, Scientific Institute and University Ospedale San Raffaele, Milan, Italy.

Address correspondence and reprint requests to Dr. M. Filippi, Neuroimaging Research Unit, Department of Neuroscience, Scientific Institute and University Ospedale San Raffaele, Via Olgettina 60, 20132 Milan, Italy; e-mail: filippi.massimo{at}hsr.it

Objective: To formally validate metrics derived from conventional MRI as surrogate endpoints for relapse rate in MS.

Background: Although metrics derived from MRI are used widely in clinical trials of MS, a formal statistical validation of MRI metrics as surrogate endpoints for clinical outcome in MS is lacking.

Methods: A validation procedure was applied to clinical and MRI data collected in the context of a randomized, double-blind, placebo-controlled trial of glatiramer acetate in patients with relapsing-remitting MS. The four Prentice operational criteria were applied to assess surrogacy for the number of new enhancing lesions, the percentage change of T2 lesion volume, and a composite MRI score based on these two metrics.

Results: The results of this analysis show that all three MRI measures considered by the authors had a behavior compatible with the Prentice criteria for valid surrogates. The composite MRI score correlated with relapses and accounted for much of the treatment effect on relapse rate.

Conclusions: This preliminary study suggests that conventional MRI metrics might serve as valid surrogate endpoints in MS trials with glatiramer acetate or treatments thought to have a similar mode of action.




This article has been cited by other articles:


Home page
 Mult SclerHome page
D Bar-Zohar, F Agosta, D Goldstaub, and M Filippi
Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives
Multiple Sclerosis, July 1, 2008; 14(6): 719 - 727.
[Abstract] [PDF]

Home page
 Am. J. Neuroradiol.Home page
D.J. Rigotti, M. Inglese, J.S. Babb, M. Rovaris, B. Benedetti, M. Filippi, R.I. Grossman, and O. Gonen
Serial Whole-Brain N-Acetylaspartate Concentration in Healthy Young Adults
AJNR Am. J. Neuroradiol., October 1, 2007; 28(9): 1650 - 1651.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Neuroradiol.Home page
B. Benedetti, D.J. Rigotti, S. Liu, M. Filippi, R.I. Grossman, and O. Gonen
Reproducibility of the Whole-Brain N-Acetylaspartate Level across Institutions, MR Scanners, and Field Strengths
AJNR Am. J. Neuroradiol., January 1, 2007; 28(1): 72 - 75.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
P. W. O'Connor, D. Li, M. S. Freedman, A. Bar-Or, G.P.A. Rice, C. Confavreux, D. W. Paty, J. A. Stewart, R. Scheyer, and on behalf of the Teriflunomide Multiple Sclerosis
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses
Neurology, March 28, 2006; 66(6): 894 - 900.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
J. Sastre-Garriga, G. T. Ingle, M. Rovaris, N. Tellez, B. Jasperse, D. R. Altmann, B. Benedetti, V. L. Stevenson, M. Cercignani, S. M. Leary, et al.
Long-term clinical outcome of primary progressive MS: Predictive value of clinical and MRI data
Neurology, August 23, 2005; 65(4): 633 - 635.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
M P Sormani, P Bruzzi, G Comi, and M Filippi
The distribution of the magnetic resonance imaging response to glatiramer acetate in multiple sclerosis
Multiple Sclerosis, August 1, 2005; 11(4): 447 - 449.
[Abstract] [PDF]

Home page
 Mult SclerHome page
F. M. Boneschi, M. Rovaris, G. Comi, and M. Filippi
The use of magnetic resonance imaging in multiple sclerosis: lessons learned from clinical trials
Multiple Sclerosis, August 1, 2004; 10(4): 341 - 347.
[Abstract] [PDF]

Home page
 BrainHome page
S. Floris, E. L. A. Blezer, G. Schreibelt, E. Dopp, S. M. A. van der Pol, I. L. Schadee-Eestermans, K. Nicolay, C. D. Dijkstra, and H. E. de Vries
Blood-brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis: A quantitative MRI study
Brain, March 1, 2004; 127(3): 616 - 627.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. P. Sormani, P. Bruzzi, K. Beckmann, K. Wagner, D. H. Miller, L. Kappos, and M. Filippi
MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN {beta}-1b
Neurology, May 13, 2003; 60(9): 1462 - 1466.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by AAN Enterprises, Inc.